Viking Therapeutics VKTX Amortization Of Financing Costs Equity Transactions
Amortization Of Financing Costs Equity Transactions at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept vktx:AmortizationOfFinancingCostsEquityTransactions.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's amortization of financing costs equity transactions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's amortization of financing costs equity transactions?
- Viking Therapeutics (VKTX) reported amortization of financing costs equity transactions of $0 in Q1 2026.
- How has Viking Therapeutics's amortization of financing costs equity transactions changed year-over-year?
- Viking Therapeutics's amortization of financing costs equity transactions decreased by 100.0% year-over-year, from $24K to $0.
- What is the long-term trend for Viking Therapeutics's amortization of financing costs equity transactions?
- Over 4 years (2021 to 2025), Viking Therapeutics's amortization of financing costs equity transactions has grown at a 31.0% compound annual growth rate (CAGR), from $19K to $56K.
- What does amortization of financing costs equity transactions mean?
- This metric represents the systematic allocation of costs incurred during the issuance of equity securities over the life of the financing arrangement. It reflects the non-cash expense associated with raising capital through equity markets, impacting the company's reported financial results. Investors monitor this to understand the ongoing cost burden of past capital-raising activities.